Evidence map›Paper›PMID 42406250›Full record

ArticleInflammopharmacology2026

REJENERA

Huseyin Emre Tepedelenlioglu, Zubeyir Elmazoglu, Sanem Gulistan Saribas, Yildiz Tutuncu, Asli F Ceylan, Çimen Karasu

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Bone reports · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Huseyin Emre TepedelenliogluDepartment of Orthopedics and Traumatology, Ankara Dışkapı Training and Research Hospital, Ankara, Turkey.
Zubeyir ElmazogluDepartment of Pharmacology, Faculty of Pharmacy, Ankara Medipol University, Ankara, Turkey.
Sanem Gulistan SaribasDepartment of Histology and Embryology, Faculty of Medicine, Health Sciences University Gulhane, Ankara, Turkey.
Yildiz TutuncuDepartment of Immunology, School of Medicine, Koç University Research Center for Translational Medicine (KUTTAM), Koç University, Istanbul, Turkey.
Asli F CeylanDepartment of Medical Pharmacology, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
Çimen KarasuDepartment of Medical Pharmacology, Cellular Stress Response and Signal Transduction Research Laboratory, Faculty of Medicine, Gazi University, Ankara, Turkey. karasu@gazi.edu.tr.ORCID https://orcid.org/0000-0002-0954-8465

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) primarly involves the degradation of joint cartilage and requires new treatments. REJENERA

Indexed as

FlavonoidsIbuprofenInflammationOleaOsteoarthritisPlant ExtractsAnimalsChondrocytesDietary SupplementsMaleNitric Oxide Synthase Type IINLR Family, Pyrin Domain-Containing 3 ProteinPlant LeavesRatsFlavonoidsIbuprofenNitric Oxide Synthase Type IINLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, ratPlant ExtractsIbuprofenInflammationNLRP3OsteoarthritisPalmitoylethanolamideREJENERAS-allylcysteineZeyEX (olive leaf extract)

Identifiers

PMID42406250
PMCPMC13525066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.